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Complex immune correlates of protection in HIV-1 vaccine efficacy trials
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| IMMUNOLOGICAL CORRELATES OF PROTECTION
7-9
Bindingantibodylevelsareutilizedascorrelatesofprotection for Hepatitis A,
10
Hepatitis B,
11
Hib polysaccharide/conjugate, 12, 13 HumanPapillomavirus, 14, 15 Measles, 16 Rubella, [17] [18] [19] Varicella, 20, 21 and Zoster.
22
Functional antibody correlates of protection are utilized as CoPwithDiphtheria,Influenza,
23-25
JapaneseEncephalitis,mumps, 26 polio, 27 rabies,smallpox, 28, 29 tetanus,andyellowfever, 
66
ResultsofsieveanalysesfromallHIV-1vaccine efficacy trials can generate testable hypotheses for mechanisms of protectiveimmunity.
| Vaccine immune correlates of virus control post infection in step/HVTN 502
Follow-upstudiesofHIV-1vaccineesthatbecomeinfected,"breakthroughinfections",canalsoprovideinsightsonthetypeandlevelof vaccine immunity that may control virus infection when acquisition does occur. Despite the lack of overall vaccine efficacy in the Step studythereweresubdominantvaccine-inducedHIV-1-specificT-cell responseswithantiviralimmunityinasubpopulationofvaccineesand the total T-cell breadth and total magnitude of the vaccine-elicited response before infection significantly correlated with lower mean viralload.
67-70
AvirussieveanalysisinStep/HVTN502identifiedsig-nificantsequencedivergenceoftheinfectingviruscomparedtothe vaccineindicatingselectionatspecificsitesinthevirusduetopotentialvaccine-inducedTcell-specificimmunepressure. increasedriskofHIV-1infection(oddsratio1.54,P=.03,q=.08) 71, 74 (Table3).
| V1V2 IgG immune correlate of decreased HIV-1 risk
IntheRV144vaccinetrial,circulatingIgGresponsestotheV2region
significantly correlated with decreased risk of infection. could mediate ADCC, neutralization, virus capture, and antibodymediatedphagocytosis. [86] [87] [88] [89] OnequestionthatarosewiththeidentificationofV1V2-specific antibodies as a correlate of decreased HIV-1 risk was whether the immunogen had a unique structure that enabled elicitation of certain specificities of antibodies. Both protein immunogens in RV144 were modified by an N-terminal 11-amino acid deletion (∆11) and additionofaherpessimplexvirus(HSV)gDprotein-derivedtag(gD) to enable efficient expression and immunoaffinity purification of the protein for production. 90 
95-97
Notably, a number of HIV-1bNAbsareofIgG3origin 98 andthesubclassisassociatedwith increased neutralization activity, complement binding and ADCC.
99
Recently,acomparisonstudyofmatchedEnvIgG1andIgG3antibodies
showedthatEnvIgG3mediatedhigherphagocytosisthanEnvIgG1. 
| Envelope IgA immune correlate
ImmunoglobulinA(IgA)isanimportantpartofhostdefensebypre- Atthetime,thistypeof interference of IgG function was only previously reported for host immunity to bacteria, the regulation of autoantibodies and ADCC activityofEBV-infectedtargetcellsinnasopharyngealcancer.
102-105
HIV-1EnvIgAinterferencewithIgG-mediatedeffectorfunctionwas subsequentlyconfirmedinanHIV-1infectioncohortstudy. 
| Polyfunctional CD4 + T cell correlate of decreased HIV transmission risk
Afollow-upimmunecorrelateanalysisidentifiedthatpolyfunctional CD4T-cellresponsescorrelatedwithdecreasedinfectionrisk. independentlyofthemagnitudeofantigen-specificT-cellresponses.
| Complex correlate of HIV-1 transmission risk in RV144
Multiple components of the immune system can act on pathogens 
| Impact of HIV-1 genetic diversity on immune correlates
ConsiderationofthegeneticvariabilityofHIV-1forimprovedHIV-1 vaccinedesigniscomplex.
119
TheHIV-1envelopeproteinsequence 
| Host genetics and HIV-1 vaccine responses
Innate and adaptive immunity to pathogens and vaccination can be 
129-131
Recently, multivariate approaches, based on nonhypothesisdriven,orunbiased,approachesoftheimmuneresponseto 
| THE NEXT HIV-1 EFFICACY TRIALS
Modeling the impact of HIV-1 vaccine efficacy on new infections has been studied for a number of scenarios and suggests that even moderatelyefficaciousvaccineregimenscanhaveasignificantimpact oncontrollingthenumberofnewHIV-1infections.Oneexampleis amodelingstudyoftheimpactofanHIVvaccinewith70%efficacy thatestimatedadramatic44%reductioninnewinfectionsoverthe firstdecade.
139
The global burden of HIV-1/AIDS is especially concentrated and rising in sub-Saharan Africa. Althoughnotavaccine,passiveinfusionstudieswithdifferentspecificitiesandpotenciesofbnAbswillprovidecriticalproofofconcept information as to whether a bNAb, when present before infection canprotectagainstacquisition,and,ifso,inwhatconcentrationsand specificitiesarenecessary.
145
Excitingdevelopmentsinantibodyengineering for improved neutralization potency and breadth, durability, andeffectorfunctionwillfurtherenrichunderstandingofwhatconstitutesprotectiveimmunity.
146
Theseresultswillhelpguideandfocus currentvaccinestudiesthataimtoinducethesetypesofantibodies. 
| Immune measurements
| Genital mucosal immunity
| Immune response durability
Maintenanceofvaccine-elicitedimmuneresponsesiscriticalforvaccineefficacy.Antibodyresponseselicitedbyseveralvaccinessuchas measleshavethelongestdurability,whereasresponsestotetanusand diphtheriawerecomparablyshorter. 
| CONCLUSIONS
Although existing prevention strategies, including the scale up of ARTwithstrategieslikepre-exposureprophylaxis(PreP), [150] [151] [152] antiretroviraltreatmentforprevention, 153, 154 implementationofmalecircumcision, 155, 156 andtopicalmicrobicides 157 inhighlyendemicareas, haveprovensuccessfulinlargescaletrials,thenumberofnewinfections has not substantially diminished.
140
There was a peak of new infectionsin1997at3.3millionthatdroppedto2.5millionin2005
and has stayed at this number for over the last 10years. 
